Kumar Avinash, Rathi Ekta, Kini Suvarna Ganesh
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104 India.
Manipal Mc Gill Centre for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka 576104 India.
3 Biotech. 2022 Sep;12(9):240. doi: 10.1007/s13205-022-03286-0. Epub 2022 Aug 23.
Spike (S) proteins are an attractive target as it mediates the binding of the SARS-CoV-2 to the host through ACE-2 receptors. We hypothesize that the screening of the S protein sequences of all the seven known HCoVs would result in the identification of potential multi-epitope vaccine candidates capable of conferring immunity against various HCoVs. In the present study, several machine learning-based tools were employed to design a broad-spectrum multi-epitope vaccine candidate targeting the S protein of seven known strains of human coronaviruses. Herein, multiple B-cell epitopes and T-cell epitopes (CTL and HTL) were predicted from the S protein sequences of all seven known HCoVs. Post-prediction they were linked together with an adjuvant to construct a potential broad-spectrum vaccine candidate. Secondary and tertiary structures were predicted and validated, and the refined 3D-model was docked with an immune receptor. The vaccine candidate was evaluated for antigenicity, allergenicity, solubility, and its ability to achieve high-level expression in bacterial hosts. Finally, the immune simulation was carried out to evaluate the immune response after three vaccine doses. The designed vaccine is antigenic (with or without the adjuvant), non-allergenic, binds well with TLR-3 receptor and might elicit a diverse and strong immune response.
The online version contains supplementary material available at 10.1007/s13205-022-03286-0.
刺突(S)蛋白是一个有吸引力的靶点,因为它介导严重急性呼吸综合征冠状病毒2(SARS-CoV-2)通过血管紧张素转换酶2(ACE-2)受体与宿主结合。我们假设,对所有七种已知人类冠状病毒(HCoV)的S蛋白序列进行筛选,将能够鉴定出潜在的多表位疫苗候选物,从而赋予针对各种HCoV的免疫力。在本研究中,使用了几种基于机器学习的工具来设计一种针对七种已知人类冠状病毒株S蛋白的广谱多表位疫苗候选物。在此,从所有七种已知HCoV的S蛋白序列中预测了多个B细胞表位和T细胞表位(细胞毒性T淋巴细胞表位和辅助性T淋巴细胞表位)。预测后,它们与一种佐剂连接在一起,构建一个潜在的广谱疫苗候选物。预测并验证了二级和三级结构,将优化后的三维模型与一种免疫受体进行对接。对该疫苗候选物的抗原性、致敏性、溶解性及其在细菌宿主中实现高水平表达的能力进行了评估。最后,进行了免疫模拟,以评估三次疫苗接种后的免疫反应。所设计的疫苗具有抗原性(无论有无佐剂),无致敏性,与Toll样受体3(TLR-3)受体结合良好,可能引发多样而强烈的免疫反应。
在线版本包含可在10.1007/s13205-022-03286-0获取的补充材料。